
photo by Getty Images/courtesy of Cedars Sinai Medical Center
Dr. Jonathan Grein, director of hospital epidemiology at Cedars-Sinai, co-authored an analysis of the experimental drug remdesivir, which was given to severely ill COVID-19 patients through a compassionate use program. (photo by Getty Images/courtesy of Cedars Sinai Medical Center)
In a small group of patients hospitalized with severe complications of COVID-19 and treated with the experimental antiviral drug remdesivir, clinical improvement was observed in 68% of patients treated, according to an analysis co-authored by Dr. Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center.
The results were from a study conducted among patients who received the drug by March 7 in the United States, Europe, Canada and Japan, and were published at the same time Cedars-Sinai is continuing to analyze remdesivir as a therapeutic option for patients as part of an international clinical study sponsored by the National Institutes of Health.
The experimental therapy was given to patients through a compassionate use program that allows providers access to treatments not yet approved by the Food and Drug Administration when a patient has a life-threatening condition and no other options are available. The analysis, published online on April 13 by the New England Journal of Medicine, evaluated data from 53 patients who received at least one dose of remdesivir by March 7. The effort was led by Gilead Sciences, the pharmaceutical company that makes the experimental drug.
The study showed that 68% of patients treated with remdesivir demonstrated an improvement in the level of oxygen support they needed over a median follow up of 18 days from the first dose of the drug. Of the 34 patients who had been intubated and required support from mechanical ventilators, 57% had their breathing tubes taken out. Also, 47% of all patients were discharged from the hospital following treatment with remdesivir.
“Currently, there is no proven treatment for COVID-19. We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said Grein, who also leads the Special Pathogens Response Team at Cedars-Sinai. “We look forward to the results of controlled clinical trials to potentially validate these findings.”
Compassionate use programs are less stringent than randomized controlled studies like the one in which Cedars-Sinai is currently involved, which compares patients who are receiving the experimental treatment to patients receiving the standard treatment. For information, visit cedars-sinai.org.











0 Comment